Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCS101
- Development stage
- Unknown
- Lead developer
- LifeBiotic
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
LCS101 is a multi-component botanical formula developed by Zen Herbs Inc., based on the principles of Traditional Chinese Medicine (TCM). It is composed of extracts from 14 botanicals, including *Astragalus membranaceus*, *Poria cocos*, *Atractylodes macrocephala*, *Lycium chinense*, *Ligustrum lucidum*, *Paeonia lactiflora*, *Paeonia obovata*, *Citrus reticulata*, *Ophiopogon japonicus*, *Millettia reticulata*, *Oldenlandia diffusa*, *Scutellaria barbata*, *Prunella vulgaris*, and *Glehnia littoralis*. The formula is primarily investigated as a complementary therapeutic to reduce the toxic side effects of chemotherapy, such as anemia, leukopenia, and neutropenia, particularly in breast cancer patients. LCS101 exhibits immunomodulatory properties, including the activation of natural killer (NK) cells and T-cell proliferation, and demonstrates selective anticancer activity by inducing apoptosis and necrosis in cancer cells while protecting healthy, non-tumorigenic cells from chemotherapy-induced damage.
- Other names
- LCS101LCS-101LCS 101
Beyond the preview
Go deeper on LCS101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCS101.